Elizabeth Vadas

President

InSciTech Inc.

Canada

Professional Summary

Elizabeth B. Vadas received her PhD in Physical Chemistry from McGill University in Montreal. She obtained her undergraduate degree in colloid and surface chemistry in Budapest, Hungary. Following postdoctoral training in the Department of Biochemistry at McGill she joined Merck Frosst, the Canadian subsidiary of Merck & Co. in 1980 where she has spent 22 years in the department of Pharmaceutical Research and Development. Over the years she has been involved in the early characterization and formulation development of many new chemical entities discovered at the Merck Frosst Centre for Therapeutic Research while taking on increasing management responsibilities. Her most significant technical accomplishments at Merck Frosst were the product development efforts of the department under her leadership, which lead to worldwide regulatory approval of several products, among them SINGULAIR®, Merck’s new asthma therapy, and VIOXX® and ARCOXIA™, two Cox-2 inhibitors for the treatment of pain, osteoarthritis and rheumatoid arthritis. In the mid 2002 Dr. Vadas decided to take early retirement to establish her own consulting company InSciTech Inc., a company providing integrated solutions for scientific and technical problems faced by life science companies in the compound selection, characterization and product development areas. Dr. Vadas’ main scientific interests are in the area of pharmaceutics, particularly in solid state chemistry and physics, drug excipient interactions and identifying appropriate means of delivering molecules of low solubility. She has been an Adjunct Professor of Pharmaceutics between 1995 and 2005 at the Faculty of Pharmacy, University of Montreal. She also has lectured and published widely and has received numerous scientific and management awards. Elizabeth attributes her success to her intellect, integrity and experience.

Skills

Specialization

                Pharmaceutics,  Compound Characterization and Selection, Formulation Development, Biopharmaceutics, Process development, Technology Transfer, Validation, Drug Delivery, Regulatory            Submission, Life Sciences